- Home
- CRVS vs HCAT Comparison
CRVS vs HCAT Comparison
Compare CRVS & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- HCAT
- Stock Information
- Founded
- CRVS 2014
- HCAT 2008
- Country
- CRVS United States
- HCAT United States
- Employees
- CRVS N/A
- HCAT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- HCAT Computer Software: Programming Data Processing
- Sector
- CRVS Health Care
- HCAT Technology
- Exchange
- CRVS Nasdaq
- HCAT Nasdaq
- Market Cap
- CRVS 305.4M
- HCAT 259.8M
- IPO Year
- CRVS 2016
- HCAT 2019
- Fundamental
- Price
- CRVS $4.10
- HCAT $3.52
- Analyst Decision
- CRVS Strong Buy
- HCAT Buy
- Analyst Count
- CRVS 4
- HCAT 11
- Target Price
- CRVS $15.00
- HCAT $8.00
- AVG Volume (30 Days)
- CRVS 445.0K
- HCAT 448.8K
- Earning Date
- CRVS 08-12-2025
- HCAT 08-07-2025
- Dividend Yield
- CRVS N/A
- HCAT N/A
- EPS Growth
- CRVS N/A
- HCAT N/A
- EPS
- CRVS N/A
- HCAT N/A
- Revenue
- CRVS N/A
- HCAT $311,274,000.00
- Revenue This Year
- CRVS N/A
- HCAT $11.21
- Revenue Next Year
- CRVS N/A
- HCAT $9.12
- P/E Ratio
- CRVS N/A
- HCAT N/A
- Revenue Growth
- CRVS N/A
- HCAT 4.88
- 52 Week Low
- CRVS $2.47
- HCAT $3.49
- 52 Week High
- CRVS $10.00
- HCAT $9.24
- Technical
- Relative Strength Index (RSI)
- CRVS 44.93
- HCAT 38.75
- Support Level
- CRVS $4.58
- HCAT $3.79
- Resistance Level
- CRVS $4.98
- HCAT $4.12
- Average True Range (ATR)
- CRVS 0.23
- HCAT 0.19
- MACD
- CRVS -0.04
- HCAT -0.03
- Stochastic Oscillator
- CRVS 13.79
- HCAT 7.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About HCAT Health Catalyst Inc
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.